{"FP": [{"generated": ["complete normalization"], "gold": [], "text": "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings."}, {"generated": ["numerous"], "gold": [], "text": "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21]."}, {"generated": ["50 \u03bcl", "20 \u03bcl", "250 ng", "2.5 \u00d7 HotMasterMix"], "gold": [], "text": "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM)."}, {"generated": ["50 \u03bcl", "20 \u03bcl", "250 ng", "2.5 \u00d7 HotMasterMix"], "gold": [], "text": "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM)."}, {"generated": ["50 \u03bcl", "20 \u03bcl", "250 ng", "2.5 \u00d7 HotMasterMix"], "gold": [], "text": "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM)."}, {"generated": ["50 \u03bcl", "20 \u03bcl", "250 ng", "2.5 \u00d7 HotMasterMix"], "gold": [], "text": "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM)."}, {"generated": ["42 mg/kg"], "gold": [], "text": "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD)."}, {"generated": ["\u00b115%"], "gold": [], "text": "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%."}, {"generated": ["10 mg/mL"], "gold": [], "text": "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water."}, {"generated": ["mean \u00b1 SD", "ratios"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["mean \u00b1 SD", "ratios"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["100 mg"], "gold": [], "text": "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer."}, {"generated": ["maximum plasma concentration"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["standard deviation", "mean"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["standard deviation", "mean"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["standard deviation", "mean"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["standard deviation", "mean"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["P"], "gold": [], "text": "***P < 0.0001."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["mean \u00b1 standard deviation", "measures", "dosages", "drug amounts", "dosage amounts", "doses", "concentrations", "values", "drug dosage amounts", "drug doses", "drug dosage concentrations", "drug concentrations", "results", "quantities", "dosage"], "gold": [], "text": "Data shown are the means \u00b1 S.D."}, {"generated": ["triplicate determinations"], "gold": [], "text": "of triplicate determinations."}, {"generated": ["150 \u03bcL", "1 ng/mL"], "gold": [], "text": "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves."}, {"generated": ["150 \u03bcL", "1 ng/mL"], "gold": [], "text": "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["five", "CV", "six", "independent experiments", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["five", "CV", "six", "independent experiments", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["five", "CV", "six", "independent experiments", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["five", "CV", "six", "independent experiments", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["five", "CV", "six", "independent experiments", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["1000 mg", "1000 mg \u00d7 4 times", "8 tablets"], "gold": ["1000 mg"], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["1000 mg", "1000 mg \u00d7 4 times", "8 tablets"], "gold": ["1000 mg"], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["1000 mg \u00d7 4 times a day", "7680 mg", "1000 once a day"], "gold": ["1000 mg", "7680 mg"], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["1000 mg \u00d7 4 times a day", "7680 mg", "1000 once a day"], "gold": ["1000 mg", "7680 mg"], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["45"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["earlier study"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["42"], "gold": [], "text": "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements."}, {"generated": ["12", "11"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["12", "11"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["18"], "gold": [], "text": "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms."}, {"generated": ["5ml"], "gold": [], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": ["9%"], "gold": [], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": ["quantities found in text"], "gold": [], "text": "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials."}, {"generated": ["27"], "gold": [], "text": "[27] In the study performed by Roozbeh et al."}, {"generated": ["population PKPD parameter estimates"], "gold": [], "text": "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3."}, {"generated": ["10, 12"], "gold": [], "text": "It therefore was recommended that they should be avoided in the elderly [10, 12]."}, {"generated": ["600 mg"], "gold": ["600\u2009mg"], "text": "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets."}, {"generated": ["toda quantidade"], "gold": [], "text": "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais."}, {"generated": ["Nenhum"], "gold": [], "text": "Apoio financeiro: Nenhum."}, {"generated": ["160/100 mmHg", "180 mg/dL"], "gold": ["180\u00a0mg/dL", "160/100\u00a0mmHg"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["160/100 mmHg", "180 mg/dL"], "gold": ["180\u00a0mg/dL", "160/100\u00a0mmHg"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["0.54\u20131.32 pg/mL"], "gold": [], "text": "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL)."}, {"generated": ["V05895B"], "gold": [], "text": "V05895B; Arkopharma, Madrid, Spain)."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["120 mg"], "gold": ["120\u00a0mg"], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": ["240-mg", "1 week"], "gold": ["240-mg"], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["unclear risk of bias", "high risk of bias"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["unclear risk of bias", "high risk of bias"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["2012"], "gold": [], "text": "2012)."}, {"generated": ["approximatly 15 min"], "gold": [], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": ["22 compounds"], "gold": [], "text": "A total of 22 compounds were identified or tentatively identified (Figure 1)."}, {"generated": ["the whole experiments"], "gold": [], "text": "conceived and designed the whole experiments."}, {"generated": ["described previously"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["p < 0.01", "p < 0.05"], "gold": [], "text": "* p < 0.05, ** p < 0.01."}, {"generated": ["p < 0.01", "p < 0.05"], "gold": [], "text": "* p < 0.05, ** p < 0.01."}, {"generated": ["5500 V", "500\u00b0C"], "gold": [], "text": "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C."}, {"generated": ["5500 V", "500\u00b0C"], "gold": [], "text": "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C."}, {"generated": ["0.05", "66.77%", "41.06%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["0.05", "66.77%", "41.06%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["0.05", "66.77%", "41.06%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["quantities"], "gold": [], "text": "; supervision, K.M.A."}, {"generated": ["described entities"], "gold": [], "text": "All authors have read and agreed to the published version of the manuscript."}, {"generated": ["APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["60 degrees/second", "2 min", "5"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["60 degrees/second", "2 min", "5"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["60 degrees/second", "2 min", "5"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["[124]", "[104]"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["[124]", "[104]"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["Table S4"], "gold": [], "text": "Table S4."}, {"generated": ["1.0 mL"], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["Ammonia"], "gold": [], "text": "Ammonia was used during derivatization since the reaction is optimal at basic pH."}, {"generated": ["2016"], "gold": [], "text": "2016)."}, {"generated": ["six rats"], "gold": [], "text": "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats."}, {"generated": ["significantly different", "p\u00a0<\u00a00.001"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different", "p\u00a0<\u00a00.001"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["9"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["significantly different", "p\u00a0<\u00a00.001"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different", "p\u00a0<\u00a00.001"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["indomethacin"], "gold": [], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": ["high relative quantities"], "gold": [], "text": "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16]."}, {"generated": ["7.2"], "gold": [], "text": "7.2."}, {"generated": ["MBI"], "gold": [], "text": "MBI, mechanism\u2010based inhibition Go to: 4."}, {"generated": ["quantities"], "gold": [], "text": "Competing interests          The authors have declared no conflicts of interests."}, {"generated": ["fifty percent"], "gold": [], "text": "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations."}, {"generated": ["2000"], "gold": [], "text": "(2000)."}, {"generated": ["34860-2.5L-R"], "gold": [], "text": "34860-2.5L-R) and ammonium acetate (catalog No."}, {"generated": ["half-maximal inhibitory concentration"], "gold": [], "text": "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No."}, {"generated": ["P", "S4"], "gold": [], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": ["P", "S4"], "gold": [], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": ["S8"], "gold": [], "text": "S8)."}, {"generated": ["100 \u03bcg/mL", "500 \u03bcg/mL"], "gold": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["100 \u03bcg/mL", "500 \u03bcg/mL"], "gold": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["absolute z-score", "level of HDI relevancy"], "gold": [], "text": "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS."}, {"generated": ["absolute z-score", "level of HDI relevancy"], "gold": [], "text": "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS."}, {"generated": ["12 traditional herbs"], "gold": [], "text": "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010)."}, {"generated": ["no specific quantities"], "gold": [], "text": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, {"generated": ["13.3", "15.00"], "gold": [], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": ["13.3", "15.00"], "gold": [], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": ["ad libitum"], "gold": [], "text": "Food and water were supplied ad libitum."}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["1 mg", "50 mg", "1 mcg", "10 mg", "200 mg", "500 mcg", "2 mcg", "5 mg", "5 mcg", "100 mg", "20 mg", "2 mg"], "gold": [], "text": "et Zucc.)"}, {"generated": ["135"], "gold": [], "text": "This is debated, and there are hints to possible beneficial effects [135]."}, {"generated": ["7.5", "28%", "15"], "gold": ["between 7.5 and 15 mg", "+28%"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["7.5", "28%", "15"], "gold": ["between 7.5 and 15 mg", "+28%"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["7.5", "28%", "15"], "gold": ["between 7.5 and 15 mg", "+28%"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["two millennia"], "gold": [], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": ["98"], "gold": [], "text": "no interaction [98]."}, {"generated": ["25 \u03bcg/ml"], "gold": ["25\u00a0\u03bcg/ml"], "text": "The activation was highest at 25\u00a0\u03bcg/ml concentration."}], "FN": [{"generated": [], "gold": ["1%", "200 \u03bcL", "10%"], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": [], "gold": ["1%", "200 \u03bcL", "10%"], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": [], "gold": ["1%", "200 \u03bcL", "10%"], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": [], "gold": ["0.1%", "0.1% (v/v)"], "text": "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO."}, {"generated": [], "gold": ["0.1%", "0.1% (v/v)"], "text": "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO."}, {"generated": [], "gold": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"], "text": "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml)."}, {"generated": [], "gold": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"], "text": "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml)."}, {"generated": [], "gold": ["3 mg/kg", "5 mg/kg"], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": [], "gold": ["3 mg/kg", "5 mg/kg"], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": [], "gold": ["1000 mg", "7680 mg"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": [], "gold": ["1000 mg", "7680 mg"], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["1000 mg \u00d7 4 times a day", "7680 mg", "1000 once a day"], "gold": ["1000 mg", "7680 mg"], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": [], "gold": ["1,200 mg"], "text": "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo."}, {"generated": [], "gold": ["1200 mg", "1200mg"], "text": "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group."}, {"generated": [], "gold": ["1200 mg", "1200mg"], "text": "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group."}, {"generated": [], "gold": ["10\u2009mg"], "text": "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess."}, {"generated": ["600 mg"], "gold": ["600\u2009mg"], "text": "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets."}, {"generated": [], "gold": ["500\u2009mg"], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": [], "gold": ["38\u2009mg/kg bw"], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": [], "gold": ["1000 mg", "600 mg"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": [], "gold": ["1000 mg", "600 mg"], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["160/100 mmHg", "180 mg/dL"], "gold": ["180\u00a0mg/dL", "160/100\u00a0mmHg"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["160/100 mmHg", "180 mg/dL"], "gold": ["180\u00a0mg/dL", "160/100\u00a0mmHg"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["0.5\u20132.0 g/kg"], "text": "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12]."}, {"generated": [], "gold": ["498"], "text": "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3."}, {"generated": [], "gold": ["<50 copies/ml"], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["8 days", "240 mg", "120 mg", "twice daily"], "gold": ["120\u00a0mg", "240\u00a0mg"], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["120 mg"], "gold": ["120\u00a0mg"], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": [], "gold": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": [], "gold": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": [], "gold": ["2 \u00d7 10"], "text": "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China)."}, {"generated": [], "gold": ["25 mg/kg"], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": [], "gold": ["25 mg/kg)"], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": [], "gold": ["40 mg/kg"], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": [], "gold": ["5\u2009mg"], "text": "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec."}, {"generated": [], "gold": ["4.5\u2009mg/200\u2009g BW"], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": [], "gold": ["6"], "text": "(n\u00a0=\u00a06)."}, {"generated": [], "gold": ["1.7\u20132.5", "1.875 mg"], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": [], "gold": ["1.7\u20132.5", "1.875 mg"], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": [], "gold": ["6 g"], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": [], "gold": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": [], "gold": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "text": "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination."}, {"generated": [], "gold": ["500 mg"], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": ["100 \u03bcg/mL", "500 \u03bcg/mL"], "gold": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["100 \u03bcg/mL", "500 \u03bcg/mL"], "gold": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": [], "gold": ["74.27\u2009\u00b5mol/L"], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": [], "gold": ["74.27\u2009\u00b5mol/L"], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": [], "gold": ["500 mg"], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": [], "gold": ["5 ppm"], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}, {"generated": ["7.5", "28%", "15"], "gold": ["between 7.5 and 15 mg", "+28%"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["7.5", "28%", "15"], "gold": ["between 7.5 and 15 mg", "+28%"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["25 \u03bcg/ml"], "gold": ["25\u00a0\u03bcg/ml"], "text": "The activation was highest at 25\u00a0\u03bcg/ml concentration."}]}